Decision Time In an earlier post I wrote about my opportunity to participate in the clinical trial: Randomized phase II 2×2 factorial trial of the addition of carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel followed by dose-dense AC in hormone receptor-poor/HER2-negative resectable breast cancer. Boy,...